On November
19, 2001 the federal Food and Drug Administration issued a consumer
warning urging users of Lipokinetix to stop taking it, and consult
their physician if they are experiencing symptoms possibly associated
with Lipokinetix. Among others, these symptoms include nausea, weakness
or fatigue, fever, abdominal pain or change in skin color. Lipokinetix
has also been associated with serious liver damage.
This product,
marketed for weight loss, contains norephedrine (PPA), caffeine,
yohimbine, diiodothyronine and sodium usniate. Of those affected
with liver injury, no apparent cause was identified other than the
use of Lipokinetix. Liver damage has developed in patients between
two weeks and three months following the beginning of Lipokinetix
use.
